Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Burtness

Showing results (51-60 of 184) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyBarbara Burtness, Meredith A Goldwasser, William Flood, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|April 4, 2003
Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current eraIsao Mitani, Diwakar Jain, Tammy M Joska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2021
Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?Anthony J Cmelak, Robert L Ferris, Allen M Chen, et al.
The Lancet. Oncology|September 3, 2013
Aurora kinases in head and neck cancerRanee Mehra, Ilya G Serebriiskii, Barbara Burtness, et al.
Cancer|March 16, 2017
TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinomaMichael Hajek, Andrew Sewell, Susan Kaech, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?Lori J Wirth, Barbara Burtness, Cherie-Ann O Nathan, et al.
Cancer|March 18, 2024
The role of surgery and deescalation for HPV-related oropharyngeal cancerKevin J Contrera, Mihir R Patel, Barbara Burtness, et al.
Trials|November 30, 2014
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trialBarbara Burtness, Jean P Bourhis, Jan B Vermorken, et al.
Cancer|January 20, 2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, et al.
Transfusion|March 27, 2004
A preclinical xenotransplantation animal model to assess human hematopoietic stem cell engraftmentMaria K Angelopoulou, Henry Rinder, Chao Wang, et al.
Pageof 19

Showing results (51-60 of 184) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyBarbara Burtness, Meredith A Goldwasser, William Flood, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|April 4, 2003
Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current eraIsao Mitani, Diwakar Jain, Tammy M Joska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2021
Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?Anthony J Cmelak, Robert L Ferris, Allen M Chen, et al.
The Lancet. Oncology|September 3, 2013
Aurora kinases in head and neck cancerRanee Mehra, Ilya G Serebriiskii, Barbara Burtness, et al.
Cancer|March 16, 2017
TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinomaMichael Hajek, Andrew Sewell, Susan Kaech, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?Lori J Wirth, Barbara Burtness, Cherie-Ann O Nathan, et al.
Cancer|March 18, 2024
The role of surgery and deescalation for HPV-related oropharyngeal cancerKevin J Contrera, Mihir R Patel, Barbara Burtness, et al.
Trials|November 30, 2014
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trialBarbara Burtness, Jean P Bourhis, Jan B Vermorken, et al.
Cancer|January 20, 2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, et al.
Transfusion|March 27, 2004
A preclinical xenotransplantation animal model to assess human hematopoietic stem cell engraftmentMaria K Angelopoulou, Henry Rinder, Chao Wang, et al.
Pageof 19